H.R. 5526

Status: In committee

Biosimilar Red Tape Elimination Act

Sponsored by August Pfluger (Republican-TX-11)

Topics

Cosponsors

Actions

Roll calls

Amendments

Related bills

Actions

Sep 19, 2025 · Library of Congress

Introduced in House

Sep 19, 2025 · Library of Congress

Introduced in House

Sep 19, 2025 · House floor actions

Referred to the House Committee on Energy and Commerce.

Latest activity

1 event unlock with a free account

1 rulemaking this week

Create free account →

July 2026

Lobbying reported · Whitmer & Worrall · Jul 22

Whitmer & Worrall reported 2nd Quarter (Apr 1 - June 30) lobbying for Campaign For Sustainable Drug Pricing (csrxp) — $50,000

BillsH.R. 1262 H.R. 1843 H.R. 3160 H.R. 3269 H.R. 3789 H.R. 4570 H.R. 5526 H.R. 6485 S. 43 S. 1032 S. 1040 S. 1041 S. 1096 S. 1414 S. 1546 S. 1954 S. 2658 S. 3014

Lobbying reported · National Taxpayers Union · Jul 21

National Taxpayers Union reported 2nd Quarter (Apr 1 - June 30) lobbying for National Taxpayers Union — $30,000

Lobbying reported · Covington & Burling · Jul 20

Covington & Burling reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research Manufacturers Of America — $220,000

BillsH.R. 2715 H.R. 5526 H.R. 7953 H.R. 8646 S. 1414 S. 1954 S. 2658 S. 3014

Lobbying reported · American College of Rheumatology · Jul 20

American College of Rheumatology reported 2nd Quarter (Apr 1 - June 30) lobbying for American College of Rheumatology — $180,000

Lobbying reported · America's Health Insurance Plans (ahip) · Jul 20

America's Health Insurance Plans (ahip) reported 2nd Quarter (Apr 1 - June 30) lobbying for America's Health Insurance Plans (ahip) — $3,010,000

BillsH.R. 1 H.R. 247 H.R. 379 H.R. 584 H.R. 608 H.R. 610 H.R. 842 H.R. 935 H.R. 950 H.R. 957 H.R. 1096 H.R. 1117 H.R. 1157 H.R. 1162 H.R. 1397 H.R. 1403 H.R. 1523 H.R. 1614 H.R. 1627 H.R. 1775 H.R. 1776 H.R. 1805 H.R. 1867 H.R. 1899 H.R. 1924 H.R. 2013 H.R. 2045 H.R. 2049 H.R. 2079 H.R. 2199 H.R. 2309 H.R. 2433 H.R. 2450 H.R. 2528 H.R. 2533 H.R. 2553 H.R. 2554 H.R. 2571 H.R. 2586 H.R. 2610 H.R. 2636 H.R. 2741 H.R. 3000 H.R. 3023 H.R. 3069 H.R. 3415 H.R. 3493 H.R. 3527 H.R. 3546 H.R. 3701 H.R. 3789 H.R. 3808 H.R. 4093 H.R. 4206 H.R. 4231 H.R. 4313 H.R. 4317 H.R. 4406 H.R. 4559 H.R. 4605 H.R. 4623 H.R. 4641 H.R. 4710 H.R. 5081 H.R. 5145 H.R. 5243 H.R. 5281 H.R. 5371 H.R. 5509 H.R. 5526 H.R. 5582 H.R. 5584 H.R. 6010 H.R. 6232 H.R. 6248 H.R. 6255 H.R. 6361 H.R. 6703 H.R. 6951 H.R. 6974 H.R. 7023 H.R. 7064 H.R. 7164 H.R. 7189 H.R. 7409 H.R. 7537 H.R. 7727 H.R. 7778 H.R. 7787 H.R. 7790 H.R. 7803 H.R. 7837 H.R. 7871 H.R. 8270 H.R. 8375 H.R. 8377 H.R. 8684 H.R. 8779 H.R. 8875 H.R. 9393 H.R. 9504 S. 339 S. 483 S. 526 S. 529 S. 652 S. 717 S. 729 S. 752 S. 864 S. 882 S. 891 S. 931 S. 939 S. 976 S. 1040 S. 1041 S. 1056 S. 1082 S. 1096 S. 1227 S. 1261 S. 1414 S. 1637 S. 1753 S. 1816 S. 1818 S. 1847 S. 1954 S. 1973 S. 2237 S. 2289 S. 2345 S. 2355 S. 2356 S. 2497 S. 2556 S. 2620 S. 2658 S. 2709 S. 2903 S. 3014 S. 3599 S. 3642 S. 3690 S. 3727 S. 3729 S. 3750 S. 3751 S. 3762 S. 3822 S. 3829 S. 3834 S. 3848 S. 3886 S. 3990 S. 4189 S. 4332 S. 4355 S. 4384 S. 4509 S. 4512

Lobbying reported · Association for Accessible Medicines · Jul 20

Association for Accessible Medicines reported 2nd Quarter (Apr 1 - June 30) lobbying for Association for Accessible Medicines — $870,000

BillsH.R. 3160 H.R. 3269 H.R. 5526 H.R. 5811 H.R. 6485 H.R. 7148 H.R. 8269 H.R. 8339 S. 43 S. 1041 S. 1096 S. 1414 S. 1546 S. 1553 S. 1954 S. 2658 S. 3469 S. 3788

Lobbying reported · Kaiser Foundation Health Plan · Jul 20

Kaiser Foundation Health Plan reported 2nd Quarter (Apr 1 - June 30) lobbying for Kaiser Foundation Health Plan — $530,000

BillsH.R. 3269 H.R. 3514 H.R. 5429 H.R. 5526 H.R. 5582 H.R. 6248 H.R. 6644 H.R. 7148 H.R. 8800 H.R. 9393 H.R. 9504 S. 43 S. 1414 S. 1816 S. 1954 S. 2355 S. 2620 S. 2780 S. 3014 S. 3822 S. 4027 S. 4784

Lobbying reported · Fresenius Kabi USA · Jul 20

Fresenius Kabi USA reported 2nd Quarter (Apr 1 - June 30) lobbying for Fresenius Kabi USA — $580,000

BillsH.R. 3269 H.R. 5526 S. 1414 S. 1954 S. 2658

Lobbying reported · Blood Cancer United · Jul 20

Blood Cancer United reported 2nd Quarter (Apr 1 - June 30) lobbying for Blood Cancer United — $590,000

Lobbying reported · Amgen · Jul 20

Amgen reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $2,440,000

Lobbying reported · Johnson & Johnson Services · Jul 20

Johnson & Johnson Services reported 2nd Quarter (Apr 1 - June 30) lobbying for Johnson & Johnson Services — $1,440,000

Lobbying reported · Avenue Solutions · Jul 20

Avenue Solutions reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $50,000

BillsH.R. 4299 H.R. 5526 S. 1954

Lobbying reported · American Society Of Health-System Pharmacists · Jul 20

American Society Of Health-System Pharmacists reported 2nd Quarter (Apr 1 - June 30) lobbying for American Society Of Health-System Pharmacists — $260,000

Lobbying reported · Pfizer · Jul 20

Pfizer reported 2nd Quarter (Apr 1 - June 30) lobbying for Pfizer — $1,880,000

BillsH.Con.Res. 14 H.R. 1 H.R. 4299 H.R. 4930 H.R. 5178 H.R. 5526 H.R. 7391 H.R. 7837 H.R. 8646 H.R. 9102 H.R. 9260 S. 2658

Lobbying reported · Apotex · Jul 20

Apotex reported 2nd Quarter (Apr 1 - June 30) lobbying for Apotex — $730,000

BillsH.R. 5526 H.R. 6485 S. 43 S. 1954

Lobbying reported · Thorn Run Partners · Jul 20

Thorn Run Partners reported 2nd Quarter (Apr 1 - June 30) lobbying for The Biosimilars Forum — $100,000

BillsH.R. 5526 S. 1954 S. 2256

Lobbying reported · Tiber Creek Group · Jul 19

Tiber Creek Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $60,000

BillsH.R. 5526 S. 1954

Lobbying reported · Mehlman Consulting · Jul 17

Mehlman Consulting reported 2nd Quarter (Apr 1 - June 30) lobbying for Association Of Accessible Medicines — $60,000

BillsH.R. 1843 H.R. 3269 H.R. 5526 S. 43 S. 1040 S. 1302 S. 1954

Lobbying reported · Prime Therapeutics · Jul 16

Prime Therapeutics reported 2nd Quarter (Apr 1 - June 30) lobbying for Prime Therapeutics — $100,000

BillsH.R. 1227 H.R. 5526 H.R. 7148 H.R. 8143 H.R. 9393 S. 1954 S. 2355 S. 3822

Lobbying reported · Association for Clinical Oncology (ASCO) · Jul 16

Association for Clinical Oncology (ASCO) reported 2nd Quarter (Apr 1 - June 30) lobbying for Association for Clinical Oncology (ASCO) — $480,000